Telix Joins 27-Partner Thera4Care, Testing FAP Dimer with Terbium-161
Image
Melbourne – November 05, 2026 -- Telix Pharmaceuticals has joined Thera4Care, a 27-partner European consortium, and its FAP-targeting dimer DOTAGA.Glu.(FAPi)2 will enter a Phase 1 trial labelled with terbium-161 (161Tb) in metastatic solid tumors.
Consortium picks Telix's FAP dimer for a Phase 1 trial with terbium-161
The trial will assess the safety profile and preliminary activity of 161Tb-DOTAGA.Glu.(FAPi)2 in patients with FAP-expressing metastatic solid tumors. The initial focus is ovarian cancer, pancreatic cancer and sarcomas. Telix says this aligns closely with its own development plans for TLX400-Tx, the lutetium-177 (177Lu) version of the same compound. The dimer has already been validated in several clinical studies.